Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

NCT03212131 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Growth Hormone Disorder
Adult Growth Hormone Deficiency
Growth Hormone Deficiency in Children

Interventions

DRUG: Somapacitan

Sponsor

Novo Nordisk A/S